Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers.
Rubinstein MM, Grisham RN, Cadoo K, Kyi C, Tew WP, Friedman CF, O'Cearbhaill RE, Zamarin D, Zhou Q, Iasonos A, Nikolovski I, Xu H, Soldan KN, Caird I, Martin M, Guillen J, Eid KT, Aghajanian C, Makker V. Rubinstein MM, et al. Gynecol Oncol. 2021 Jan;160(1):71-76. doi: 10.1016/j.ygyno.2020.10.019. Epub 2020 Nov 1. Gynecol Oncol. 2021. PMID: 33139041 Free PMC article. Clinical Trial.
Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer.
Stasenko M, Tunnage I, Ashley CW, Rubinstein MM, Latham AJ, Da Cruz Paula A, Mueller JJ, Leitao MM Jr, Friedman CF, Makker V, Soslow RA, DeLair DF, Hyman DM, Zamarin D, Alektiar KM, Aghajanian CA, Abu-Rustum NR, Weigelt B, Cadoo KA. Stasenko M, et al. Among authors: rubinstein mm. Gynecol Oncol. 2020 Jan;156(1):194-202. doi: 10.1016/j.ygyno.2019.10.028. Epub 2019 Nov 19. Gynecol Oncol. 2020. PMID: 31757464 Free PMC article.
Optimizing immunotherapy for gynecologic cancers.
Rubinstein MM, Makker V. Rubinstein MM, et al. Curr Opin Obstet Gynecol. 2020 Feb;32(1):1-8. doi: 10.1097/GCO.0000000000000603. Curr Opin Obstet Gynecol. 2020. PMID: 31833942 Free PMC article. Review.
Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway.
Rubinstein MM, Hyman DM, Caird I, Won H, Soldan K, Seier K, Iasonos A, Tew WP, O'Cearbhaill RE, Grisham RN, Hensley ML, Troso-Sandoval T, Sabbatini P, Guillen J, Selcuklu SD, Zimel C, Torrisi J, Aghajanian C, Makker V. Rubinstein MM, et al. Cancer. 2020 Mar 15;126(6):1274-1282. doi: 10.1002/cncr.32677. Epub 2019 Dec 27. Cancer. 2020. PMID: 31880826 Free PMC article. Clinical Trial.
Bevacizumab in advanced endometrial cancer.
Rubinstein MM, Dickinson S, Narayan P, Zhou Q, Iasonos A, Ma W, Lakhman Y, Makker V. Rubinstein MM, et al. Gynecol Oncol. 2021 Jun;161(3):720-726. doi: 10.1016/j.ygyno.2021.04.016. Epub 2021 Apr 22. Gynecol Oncol. 2021. PMID: 33894982 Free PMC article.
Microsatellite Instability-High Endometrial Cancers with MLH1 Promoter Hypermethylation Have Distinct Molecular and Clinical Profiles.
Manning-Geist BL, Liu YL, Devereaux KA, Paula ADC, Zhou QC, Ma W, Selenica P, Ceyhan-Birsoy O, Moukarzel LA, Hoang T, Gordhandas S, Rubinstein MM, Friedman CF, Aghajanian C, Abu-Rustum NR, Stadler ZK, Reis-Filho JS, Iasonos A, Zamarin D, Ellenson LH, Lakhman Y, Mandelker DL, Weigelt B. Manning-Geist BL, et al. Among authors: rubinstein mm. Clin Cancer Res. 2022 Oct 3;28(19):4302-4311. doi: 10.1158/1078-0432.CCR-22-0713. Clin Cancer Res. 2022. PMID: 35849120 Free PMC article.
23 results